Daniel Carpenter News
Most Popular Daniel Carpenter Story
Study reaffirms safety flags for last-minute meds
Remember that study that seemed to show that drugs FDA approved on deadline were more likley to end up with safety problems? Since its March publication in the New England Journal of Medicine, FDA... Read more...
Latest Headlines
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
